Indications: Treatment of metastatic prostate cancer (in combination with an LHRH agonist).

Cautions: consider periodic liver function tests

Contra-indications: Hypersensitivity to bicalutamide or any component of the formulation; use in women, especially women who are or may become pregnant.

Side Effects: nausea, diarrhoea, cholestasis, jaundice; asthenia, weight gain; gynaecomastia, breast tenderness, hot flushes, impotence, decreased libido; anaemia; alopecia, dry skin, hirsutism, pruritus; less commonly vomiting, abdominal pain, dyspepsia, interstitial lung disease, pulmonary fibrosis, depression, haematuria, thrombocytopenia, hypersensitivity reactions including angioneurotic oedema and urticaria; rarely cardiovascular disorders (including angina, heart failure, and arrhythmias), and hepatic failure.

Dose: Locally advanced prostate cancer at high risk of disease progression: 150 mg once daily locally advanced, non-metastatic prostate cancer when surgical castration or other medical intervention inappropriate: 150 mg once daily. Advanced prostate cancer: in combination with gonadorelin analogue or surgical castration, 50 mg once daily.